Roth Capital Reiterates Buy Rating for Flex Pharma (FLKS)

Flex Pharma (NASDAQ:FLKS)‘s stock had its “buy” rating reissued by investment analysts at Roth Capital in a research report issued to clients and investors on Wednesday. They currently have a $12.00 price objective on the biotechnology company’s stock. Roth Capital’s price target suggests a potential upside of 237.08% from the company’s previous close.

A number of other analysts have also weighed in on FLKS. Cantor Fitzgerald reiterated a “hold” rating and issued a $10.00 price objective on shares of Flex Pharma in a research note on Monday, September 25th. Zacks Investment Research upgraded shares of Flex Pharma from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research note on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $9.35.

Shares of Flex Pharma (FLKS) traded up $0.07 during trading on Wednesday, reaching $3.56. 25,000 shares of the company’s stock were exchanged, compared to its average volume of 64,050. Flex Pharma has a twelve month low of $2.68 and a twelve month high of $5.99. The firm has a market cap of $62.72, a price-to-earnings ratio of -1.76 and a beta of 3.54.

Flex Pharma (NASDAQ:FLKS) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.06. Flex Pharma had a negative net margin of 2,655.19% and a negative return on equity of 71.39%. The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.47 million. analysts expect that Flex Pharma will post -2.48 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Royce & Associates LP boosted its holdings in Flex Pharma by 29.0% during the second quarter. Royce & Associates LP now owns 312,410 shares of the biotechnology company’s stock worth $1,203,000 after buying an additional 70,210 shares in the last quarter. Sphera Funds Management LTD. purchased a new stake in Flex Pharma during the third quarter worth $2,341,000. Finally, Ameriprise Financial Inc. boosted its holdings in Flex Pharma by 10.0% during the third quarter. Ameriprise Financial Inc. now owns 720,524 shares of the biotechnology company’s stock worth $2,457,000 after buying an additional 65,699 shares in the last quarter. Hedge funds and other institutional investors own 27.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2018/01/03/roth-capital-reiterates-buy-rating-for-flex-pharma-flks.html.

About Flex Pharma

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply